Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProTaT trial of docetaxel, prednisone, and thalidomide in metastatic hormone-refractory prostate cancer
ACTRN12606000372583Phase 2Active, not recruiting
- Sponsor
- Royal North Shore Hospital
- Start
- Feb 2004
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, prednisone and thalidomide in prostate cancer (PCa), sponsored by Royal North Shore Hospital. Primary endpoints: PSA prostate specific antigen, Tumor lesion assessment and 2 more. Started Feb 2004; status: active, not recruiting.
02
Drugs
docetaxelprednisonethalidomide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ACTRN12606000372583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000372583.